Brii Biosciences Presents Promising Clinical Data to Support Ongoing Development of Novel HIV Therapeutic Candidates at IDWeek 2022
- Written by PR Newswire
 |
- Findings from two Phase 1 studies show both BRII-732 and BRII-778 are safe and well-tolerated
- Results indicate potential for oral once-weekly, long-acting combination therapy for HIV infection, supporting continued clinical development
- Additional data presented by Brii's licensing partners at IDWeek 2022 showcase breadth of Company's infectious...
